Chemomab Therapeutics LTD. 6-K Filing
Ticker: CMMB · Form: 6-K · Filed: Nov 21, 2025 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 6-K |
| Filed Date | Nov 21, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Chemomab Therapeutics LTD. (ticker: CMMB) to the SEC on Nov 21, 2025.
How long is this filing?
Chemomab Therapeutics LTD.'s 6-K filing is 1 pages with approximately 247 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 247 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2025-11-21 06:15:37
Filing Documents
- zk2534057.htm (6-K) — 11KB
- exhibit_99-1.htm (EX-99.1) — 160KB
- image00001.jpg (GRAPHIC) — 26KB
- 0001178913-25-003932.txt ( ) — 209KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant's name into English) 10 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE Chemomab Therapeutics Ltd. (the "Company") hereby furnishes under this Report of Foreign Private Issuer on Form 6-K (the "Form 6-K") the following: (i) press release, dated November 20, 2025, titled "Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Corporate Update" as Exhibit 99.1 to this Form 6-K. Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into Company's Registration Statements on Form F-3 (File No. 333-275002 and No. 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868). EXHIBIT INDEX Exhibit Description 99.1 Press Release dated November 20, 2025, titled "Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update" SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CHEMOMAB THERAPEUTICS LTD. Date: November 21, 2025 By: /s/ Sigal Fattal Sigal Fattal Chief Financial Officer